Different promising strategies have been used to reduce the risk of OHSS in patients with polycystic ovary syndrome (PCOS) including ovarian stimulation using a GnRH-antagonist protocol followed by a GnRH-agonist ovulation trigger[1], low-dose stimulation protocol using highly purified follicle-stimulation hormone[2] and treatment segmentation with elective freezing of all oocytes or embryos[3]. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.